LAUSANNE, Switzerland I October 11, 2018 I Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a radioconjugated minigastrin analogue (Debio 1124) for cancer patients.
Debio 1124 is a new-generation peptide analogue of minigastrin, coupled to the isotope 177Lutetium. It belongs to the emerging class of Peptide Receptor Radionuclide Therapies and has been designed to selectively radiate tumor cells expressing the Cholecystokinin B Receptor (CCK2R). The compound can also be used as a sensitive diagnostic tool so that an initial imaging step allows the selection of patients who are most likely to benefit from this innovative treatment.
Debio 1124 is currently being developed in advanced Medullary Thyroid Cancer and will be further investigated in other tumor types expressing CCK2R.
“Molecular-targeted radiotherapy has proven to be an efficient way to direct the tumoricidal effects of radiation while minimizing the potential damage of healthy tissues. We look forward to exploring the potential of this innovative product in the clinic and to providing new treatment options to well defined patient groups”.
Dr Carlos Chanquia, Medical Director, Debiopharm International
” PSI has once more fulfilled its societal mission with the transfer of Debio 1124 into direction of market maturity and which will hopefully contribute to improve treatment outcome of cancer patients in the future. We are proud that we will proceed with this mission in cooperation with a Swiss based pharmaceutical company such as Debiopharm“.
Dr Martin Béhé, Group Head, Center of radiopharmaceutical sciences, PSI
About the Paul Scherrer Institute
The PSI develops, builds and operates large, complex research facilities and makes them available to the national and international research community. The institute’s own key research priorities are in the fields of matter and materials, energy and environment and human health. PSI is committed to the training of future generations PSI is part of the ETH Domain, with the other members being the two Swiss Federal Institutes of Technology, ETH Zurich and EPFL Lausanne.
www.psi.ch
About Debiopharm International SA
Part of Debiopharm Group™, Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to reach out to the largest number of patients worldwide.
www.debiopharm.com
SOURCE: Debiopharm
Post Views: 147
LAUSANNE, Switzerland I October 11, 2018 I Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a radioconjugated minigastrin analogue (Debio 1124) for cancer patients.
Debio 1124 is a new-generation peptide analogue of minigastrin, coupled to the isotope 177Lutetium. It belongs to the emerging class of Peptide Receptor Radionuclide Therapies and has been designed to selectively radiate tumor cells expressing the Cholecystokinin B Receptor (CCK2R). The compound can also be used as a sensitive diagnostic tool so that an initial imaging step allows the selection of patients who are most likely to benefit from this innovative treatment.
Debio 1124 is currently being developed in advanced Medullary Thyroid Cancer and will be further investigated in other tumor types expressing CCK2R.
“Molecular-targeted radiotherapy has proven to be an efficient way to direct the tumoricidal effects of radiation while minimizing the potential damage of healthy tissues. We look forward to exploring the potential of this innovative product in the clinic and to providing new treatment options to well defined patient groups”.
Dr Carlos Chanquia, Medical Director, Debiopharm International
” PSI has once more fulfilled its societal mission with the transfer of Debio 1124 into direction of market maturity and which will hopefully contribute to improve treatment outcome of cancer patients in the future. We are proud that we will proceed with this mission in cooperation with a Swiss based pharmaceutical company such as Debiopharm“.
Dr Martin Béhé, Group Head, Center of radiopharmaceutical sciences, PSI
About the Paul Scherrer Institute
The PSI develops, builds and operates large, complex research facilities and makes them available to the national and international research community. The institute’s own key research priorities are in the fields of matter and materials, energy and environment and human health. PSI is committed to the training of future generations PSI is part of the ETH Domain, with the other members being the two Swiss Federal Institutes of Technology, ETH Zurich and EPFL Lausanne.
www.psi.ch
About Debiopharm International SA
Part of Debiopharm Group™, Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to reach out to the largest number of patients worldwide.
www.debiopharm.com
SOURCE: Debiopharm
Post Views: 147
